Enrique M. Ocio

University Name

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

70%

Pharmacotherapy

80%

Multiple Myeloma

90%

Targeted Therapy

80%

Hematology

50%

Antibody Therapy

30%

Monoclonal Antibodies

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles21

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

Article Link

Year:

2024

A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Article Link

Year:

2024

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Article Link

Year:

2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.

Article Link

Year:

2024

Adverse effects of therapeutic phlebotomies: Prospective study of 587 procedures.

Article Link

Year:

2024

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Article Link

Year:

2024

Brave new world: expanding home care in stem cell transplantation and advanced therapies with new technologies.

Article Link

Year:

2024

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Article Link

Year:

2024

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Article Link

Year:

2024

Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age

Article Link

Year:

2024

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Article Link

Year:

2023

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.

Article Link

Year:

2022

Melflufen for the treatment of multiple myeloma

Article Link

Year:

2022

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

Article Link

Year:

2021

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression

Article Link

Year:

2021

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

Article Link

Year:

2021

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

Article Link

Year:

2021

Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study

Article Link

Year:

2021

Convalescent plasma treatment for patients of 80 years and older with COVID-19 pneumonia

Article Link

Year:

2021

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

Article Link

Year:

2021

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Article Link

Year:

2021

Collaborators6

Verónica González-Calle

University Hospital of Salamanca

SPAIN

Felipe de Arriba de la Fuente

Profesor Asociado

Universidad de Murcia

SPAIN

Teresa Paíno

Universidad de Salamanca

SPAIN

María Carmen Chillón

SPAIN

Jesus F. San Miguel

SPAIN

Norma C. Gutiérrez

SPAIN

How do I reach out?

Meet Kite AI